Benchling

Benchling, Inc. is a privately held US life-sciences R&D software company founded 2012 by Sajith Wickramasekara (CEO), Ashu Singhal (President), and Cory Li. HQ at 680 Folsom Street, 8th Floor, San Francisco, CA 94107; four global offices (San Francisco, Boston, Zürich, Belfast). Customers in 32+ countries.

The company sells a unified R&D Cloud rebranded in 2025 as "the AI platform for biotech R&D." Core modules: Benchling Bioresearch (Notebook/ELN, Molecular Biology, Registry, Inventory, Workflows), Benchling Development (process/analytical method), Benchling Bioprocess, Benchling In Vivo (Overwatch Research 2022 acquisition), Benchling Biologics (PipeBio 2024 acquisition), Benchling Connect (instrument connectivity), Benchling Insights, Benchling Validated Cloud (dedicated GxP-validated tenant), and Benchling AI (October 2025).

Vendor-reported scale: 1,300+ biotech companies and "more than half of the top 50 global biopharma" as of January 2026. CEO has stated biopharma is ~80% of customers. Named pharma/biotech customers include Sanofi, Moderna, Merck (MSD), Eli Lilly, Gilead Sciences, Regeneron, Biogen, Zealand Pharma, UCB, Editas Medicine, Beam Therapeutics, Verve Therapeutics, ElevateBio, Sana Biotechnology, Mammoth Biosciences, Absci, Generate:Biomedicines, Servier, Dynavax, and New England Biolabs.

Capital raised: $412M+ across 9 rounds. Last priced round: $100M Series F at $6.1B post-money in November 2021 co-led by Franklin Templeton and Altimeter Capital. Contrary Research's secondary-market estimate put implied valuation at ~$2.4B as of September 2024 (third-party). IPO paperwork was prepared in late 2021 but has not been executed. Sacra third-party ARR estimate: ~$210M in May 2024, growing 27% YoY. April 2023 layoffs (74 employees, 9%, GTM-weighted) are the only public reduction; Tracxn lists 797 employees as of February 2026.

Life-sciences–specialized vendor with biopharma as the largest end-market (CEO has stated ~80% of customers). 1,300+ biotech customers (January 2026) including more than half of the top 50 global biopharma. Adoption pattern in Big Pharma tilts toward R&D function deployments rather than enterprise-wide rollouts (e.g., Merck collaboration is scoped to pre-clinical and clinical bioanalytical workflows; Moderna rolling from technical development teams into research).

Compliance posture is positioned for R&D and early development GxP, not commercial GMP manufacturing serialization. Benchling states the platform is "built for compliance with FDA 21 CFR Part 11, Annex 11 and EPA regulations for operating in a regulated (GxP) environment" and aligns to NIST, C5, GDPR, NCSC, and CCPA. Validation tooling references ICH Q9 and ISO/GAMP guidance. Validated Cloud offers a dedicated tenant with quarterly controlled releases, IQ/OQ documentation, and Part 11 / Annex 11 e-signature controls. DSCSA, FSMA 204, ICH Q7/Q10, MHRA/PMDA/NMPA/ANVISA/Health Canada-specific certifications are not publicly claimed. No FDA Form 483 or Warning Letter publicly cites Benchling software.

Venture-backed, not PE-owned. Total raised: $412M+ across 9 rounds. Last priced round: $100M Series F on November 18, 2021 co-led by Franklin Templeton and Altimeter Capital, with Tiger Global, Lone Pine, Sequoia, Benchmark, Andreessen Horowitz, Thrive Capital, ICONIQ, Lux Capital, and Elad Gil at $6.1B post-money. Contrary Research's secondary-market estimate put implied valuation at ~$2.4B as of September 2024 (third-party, not a primary round). No IPO has been completed; paperwork prepared in late 2021 has not been executed.

Sacra third-party ARR estimate: ~$210M in May 2024, growing 27% YoY, decelerating from a reported 175% in 2019 (unverified). Vendor-reported milestones include "triple-digit YoY revenue growth" and "169% dollar-based net expansion rate" in fiscal Q3 2021. Profitability and cash flow are not disclosed.

M&A by Benchling: Overwatch Research (Belfast, in-vivo, Feb 24 2022, undisclosed price); PipeBio (Denmark, antibody bioinformatics, Oct 20 2024, undisclosed); ReSync Bio and Sphinx Bio team acquisitions (AI tooling) announced August 20 2025, undisclosed.

Unified R&D Cloud rebranded since 2025 as "the AI platform for biotech R&D." Core modules: Benchling Bioresearch (Notebook/ELN, Molecular Biology, Registry, Inventory, Workflows); Benchling Development (process development, process characterization, analytical method development); Benchling Bioprocess (cloud-native high-throughput process development, launched 2023); Benchling In Vivo (study management, from 2022 Overwatch Research acquisition); Benchling Biologics (end-to-end AI-enhanced antibody discovery, from 2024 PipeBio acquisition); Benchling Connect (instrument connectivity, launched September 2023, 12+ instrument categories, output mapped to the Allotrope Simple Model); Benchling Insights (analytics/visualization); Benchling Validated Cloud (GxP-validated tenant with quarterly controlled releases, IQ/OQ documentation, Part 11/Annex 11 e-signature controls).

Benchling AI launched October 2025 as a "command center for scientific AI" — agents include Compose, Data Entry, Ask Mode, Deep Research. Models accessed through the platform include AlphaFold 2, Chai-1, Boltz-2, NVIDIA BioNeMo (including OpenFold2 NIM), Anthropic Claude, Google Gemini, OpenAI, and Lilly TuneLab predictive models. Recent launches: AI Connectors built on Model Context Protocol with Elicit, GXL, Seqera, Quilt, Notion, SharePoint, Snowflake (April 2026, GA May 2026); one-click ordering for biological materials with Twist Bioscience, Adaptyv, and Ginkgo Bioworks (May 2026); custom Python/R execution; HighRes Biosolutions workcell integration.

Hosted on AWS; AWS Partner Network member since 2019; listed on AWS Marketplace. AI partnerships include NVIDIA (BioNeMo NIM microservices), Anthropic (Claude for Life Sciences featured connector), and Eli Lilly TuneLab. Snowflake is supported through MCP-based AI Connectors for institutional knowledge ingestion. Microsoft Azure, Google Cloud (as a hosting partner), SAP, Oracle, Salesforce, ServiceNow, and Databricks are not publicly named as Benchling partners.

Benchling supports the Allotrope Simple Model (ASM) for instrument data interoperability and has open-sourced its ASM converters on GitHub. Explicit institutional memberships in ISPE, PDA, PQG, ASTM, GS1, USP, or IEEE are not publicly stated. Benchling Connect provides 12+ instrument-model integrations across plate readers, HPLC, qPCR, dPCR, cell counters, liquid handlers, and cell culture analyzers; JMP analytics integration is supported. Named Tier-1 SIs (Deloitte, Accenture, Capgemini, IBM, PwC, EY) are not publicly named as direct Benchling implementation partners; pharma-niche services firms publishing Benchling-specific advisory content include Clarkston Consulting and PTP (Pinnacle Technology Partners).

Email and in-app chat support via [email protected]; 24/7 coverage, regional language coverage, and named CSM tier SLAs are not publicly disclosed. Validated Cloud customers receive quarterly release packages with IQ/OQ documentation; Customer Success and Quality / Professional Services teams support implementation, validation, training, and change management (vendor does not disclose org headcount).

User community is anchored by Benchtalk, the annual user conference; the 2025 edition drew 900+ attendees across Boston (Oct 14-15) and London (Oct 22-23). Benchling also runs the Nordic Digital Science & Innovation Day in Copenhagen. A user community portal exists at benchling.com but membership figures are not disclosed. No formal Benchling-administered user/partner certification track beyond a developer Partner Program for app builders.

Certifications: SOC 2 Type 2 attestation (annually renewed; 2025 report covers Benchling AI and PipeBio Antibodies in scope), ISO/IEC 27001:2022 with additional controls of ISO/IEC 27017:2015 and ISO/IEC 27018:2019, and EU-US Data Privacy Framework certification. ISO 9001 and HITRUST are not publicly held. Regulatory posture: 21 CFR Part 11, Annex 11, EPA, NIST, C5, GDPR, NCSC, CCPA.

Analyst recognition: Benchling licenses and republishes Gartner research ("Predicts 2024: Generative AI Brings New Value to Life Sciences"). No Gartner Magic Quadrant or Forrester Wave placement names Benchling as Leader or Strong Performer. CB Insights names Benchling a "Leader" in its proprietary ESP / lab management platforms ranking. Vendor reports selection for Fast Company's top 10 most innovative companies in North America.

Leadership: CEO and co-founder Sajith Wickramasekara; President and co-founder Ashu Singhal; CPO Shawna Wolverton (ex-Salesforce, Zendesk, Planet); CMO Lindsey Irvine (ex-Salesforce, MuleSoft); CFO Ron Gill (ex-NetSuite CFO, appointed May 2024); CRO Parm Uppal (appointed May 2024); CISO Zach Powers; EMEA GM Bob Burke. A named Chief Quality / Compliance Officer is not publicly identified. Thought leadership: annual "State of Tech in Biopharma" and "Biotech AI Report" (2026 edition launched January 2026).

Press-release cadence is high — approximately monthly via PR Newswire over the last 12 months covering Moderna (May 2025), Merck (June 2025), ReSync/Sphinx acquisitions (August 2025), Benchtalk launches (October 2025), Anthropic partnership (October 2025), Lilly TuneLab (January 2026), AI Connectors (April 2026), and one-click ordering (May 2026). Active blog publishes multiple times monthly; Trust Center refreshed in 2025 to add Benchling AI and PipeBio Antibodies to SOC 2 scope.

Conference presence: SLAS, Bio-IT World, BIO, plus Benchling-owned Benchtalk in Boston and London (Benchtalk 2025 drew 900+ attendees). Notable narrative: "Rebuilding biotech for the AI era" — positioned as the system-of-record layer that AI agents and external models plug into. AWS Marketplace listing available. No Azure Marketplace, Salesforce AppExchange, or ServiceNow Store listing.